{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:12:44Z","timestamp":1791969164538,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Boehringer Ingelheim"],"award-info":[{"award-number":["Boehringer Ingelheim"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The novel positron emission tomography (PET) imaging tracer, [<jats:sup>18<\/jats:sup>F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [<jats:sup>18<\/jats:sup>F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60\u00a0min. Venous and\/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input functions were analysed using single-tissue reversible (1T2k), two-tissue irreversible (2T3k) and two-tissue reversible (2T4k) plasma input models. Simplified uptake measures, such as standardised uptake value (SUV) and tumour-to-blood (TBR) or tumour-to-plasma ratio (TPR), were evaluated for different time intervals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Whole-blood and plasma radioactivity concentrations showed rapid clearance of [<jats:sup>18<\/jats:sup>F]F-AraG. Metabolite analysis revealed a low rate of metabolism, at 70\u00a0min p.i., on average, 79% (SD\u2009=\u20099.8%) of the total radioactivity found in blood corresponded to intact [<jats:sup>18<\/jats:sup>F]F-AraG. The time activity curves were best fitted by the 2T3k model. Strong positive correlations were found for SUV (body weight (BW), lean body mass (LBM) or body surface area (BSA) corrected), TBR and TPR for any time interval between 20 and 70\u00a0min p.i. against the 2T3k-derived <jats:italic>K<\/jats:italic>\n              <jats:sub>\n                <jats:italic>i<\/jats:italic>\n              <\/jats:sub>. The correlation of TBR at 60\u201370\u00a0min p.i. with 2T3K-derived <jats:italic>K<\/jats:italic>\n              <jats:sub>\n                <jats:italic>i<\/jats:italic>\n              <\/jats:sub> (r (df\u2009=\u200920)\u2009=\u20090.87, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), was stronger than for SUV<jats:sub>BW<\/jats:sub> (r (df\u2009=\u200920)\u2009=\u20090.80, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Tumour lesion [<jats:sup>18<\/jats:sup>F]F-AraG uptake in patients with NSCLC is characterised by a 2T3k model. TBR and TPR show most potential for simplified quantification of tumour lesion [<jats:sup>18<\/jats:sup>F]F-AraG uptake in patients with NSCLC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-024-06931-3","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:01:52Z","timestamp":1728360112000},"page":"719-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-6246","authenticated-orcid":false,"given":"Jessica E.","family":"Wijngaarden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-1235","authenticated-orcid":false,"given":"Maarten","family":"Slebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna E. E.","family":"Pouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Schuit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Willemien Menke-van der Houven v","family":"Oordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idris","family":"Bahce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"6931_CR1","doi-asserted-by":"publisher","first-page":"S1181","DOI":"10.1016\/j.annonc.2020.08.2284","volume":"31","author":"J Brahmer","year":"2020","unstructured":"Brahmer J, Rodriguez-Abreu D, Robinson A, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS)\u2009\u2265\u200950%. Ann Oncol. 2020;31:S1181\u20132.","journal-title":"Ann Oncol"},{"key":"6931_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares LG, Ramalingam SS, Ciuleanu T-E, Lee J-S, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022;17:289\u2013308.","journal-title":"J Thorac Oncol"},{"key":"6931_CR3","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921\u20135.","journal-title":"Curr Biol"},{"key":"6931_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2017","unstructured":"Jim\u00e9nez-S\u00e1nchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170:927\u201338. e20.","journal-title":"Cell"},{"key":"6931_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2022.05.017","volume":"169","author":"M Slebe","year":"2022","unstructured":"Slebe M, Pouw JE, Hashemi SM, Menke-van der Houven CW, Yaqub MM, Bahce I. Current state and upcoming opportunities for immunoPET biomarkers in lung cancer. Lung Cancer. 2022;169:84\u201393.","journal-title":"Lung Cancer"},{"key":"6931_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s11307-010-0414-x","volume":"13","author":"M Namavari","year":"2011","unstructured":"Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS. Synthesis of 2\u2019-deoxy-2\u2019-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol. 2011;13:812\u20138. https:\/\/doi.org\/10.1007\/s11307-010-0414-x.","journal-title":"Mol Imaging Biol"},{"key":"6931_CR7","doi-asserted-by":"publisher","first-page":"3667417","DOI":"10.1155\/2022\/3667417","volume":"2022","author":"J Levi","year":"2022","unstructured":"Levi J, Duan H, Yaghoubi S, Packiasamy J, Huynh L, Lam T, et al. Biodistribution of a mitochondrial metabolic Tracer, [(18)F]F-AraG, in healthy volunteers. Mol Imaging. 2022;2022:3667417. https:\/\/doi.org\/10.1155\/2022\/3667417.","journal-title":"Molecular Imaging"},{"key":"6931_CR8","doi-asserted-by":"crossref","unstructured":"Sanford M, Lyseng-Williamson KA, Nelarabine. Drugs. 2008;68(4).","DOI":"10.2165\/00003495-200868040-00004"},{"key":"6931_CR9","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1158\/0008-5472.CAN-19-0267","volume":"79","author":"J Levi","year":"2019","unstructured":"Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, et al. Imaging of Activated T Cells as an early predictor of Immune response to Anti-PD-1 therapy. Cancer Res. 2019;79:3455\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0267.","journal-title":"Cancer Res"},{"key":"6931_CR10","doi-asserted-by":"crossref","unstructured":"Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B et al. The association between CD8\u2009+\u2009tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine. 2021;41.","DOI":"10.1016\/j.eclinm.2021.101134"},{"key":"6931_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00004647-200106000-00002","volume":"21","author":"RN Gunn","year":"2001","unstructured":"Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metabolism. 2001;21:635\u201352.","journal-title":"J Cereb Blood Flow Metabolism"},{"key":"6931_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6931_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s00259-018-3977-4","volume":"45","author":"A Kaalep","year":"2018","unstructured":"Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, Boellaard R. Feasibility of state of the art PET\/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6931_CR14","unstructured":"Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. Soc Nuclear Med; 2018."},{"key":"6931_CR15","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1088\/0031-9155\/51\/17\/007","volume":"51","author":"M Yaqub","year":"2006","unstructured":"Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol. 2006;51:4217.","journal-title":"Phys Med Biol"},{"key":"6931_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716\u201323.","journal-title":"IEEE Trans Autom Control"},{"key":"6931_CR17","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1158\/0008-5472.CAN-16-2953","volume":"77","author":"JA Ronald","year":"2017","unstructured":"Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D\u2019Souza A, et al. A PET imaging strategy to visualize activated T cells in Acute Graft-versus-host Disease elicited by allogenic hematopoietic cell transplant. Cancer Res. 2017;77:2893\u2013902. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2953.","journal-title":"Cancer Res"},{"key":"6931_CR18","doi-asserted-by":"crossref","unstructured":"Omidvari N, Levi J, Abdelhafez YG, Wang Y, Nardo L, Daly ME et al. Total-body dynamic imaging and kinetic modeling of [18F] F-AraG in healthy individuals and a non\u2013small cell Lung Cancer patient undergoing Anti\u2013PD-1 immunotherapy. J Nucl Med. 2024;65(9):1481-1488.","DOI":"10.2967\/jnumed.123.267003"},{"key":"6931_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s42003-020-1052-8","volume":"3","author":"T Rothenburger","year":"2020","unstructured":"Rothenburger T, McLaughlin K-M, Herold T, Schneider C, Oellerich T, Rothweiler F, et al. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. Commun Biology. 2020;3:324.","journal-title":"Commun Biology"},{"issue":"Suppl 1","key":"6931_CR20","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2967\/jnumed.108.057182","volume":"50","author":"R Boellaard","year":"2009","unstructured":"Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):S11\u201320. https:\/\/doi.org\/10.2967\/jnumed.108.057182.","journal-title":"J Nucl Med"},{"key":"6931_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jcbfm.1983.1","volume":"3","author":"CS Patlak","year":"1983","unstructured":"Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metabolism. 1983;3:1\u20137.","journal-title":"J Cereb Blood Flow Metabolism"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06931-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T09:47:34Z","timestamp":1736848054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06931-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6931"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06931-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Amsterdam University Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Andrea Thiele is an employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. CellSight Technologies (CST) is commercializing [18F]F-AraG. Jelena Levi holds an equity interest in CST and patents related to [18F]F-AraG.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}